Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 180 of 201 entries
Sorted by: Best Match Show Resources per page
Advances in particle shape engineering for improved drug delivery.

Drug discovery today

Yang Y, Nie D, Liu Y, Yu M, Gan Y.
PMID: 30342244
Drug Discov Today. 2019 Feb;24(2):575-583. doi: 10.1016/j.drudis.2018.10.006. Epub 2018 Oct 17.

Spherical particles such as liposomes and microspheres are the most common and extensively applied drug vehicles. However, researchers have come to realize the superiority of nonspherical nanoparticles. Actually, in human bodies red blood cells, gut biotics and many well-known...

Cite
Yang Y, Nie D, Liu Y, et al. Advances in particle shape engineering for improved drug delivery. Drug Discov Today. 2018;24(2):575-583doi: 10.1016/j.drudis.2018.10.006.
Yang, Y., Nie, D., Liu, Y., Yu, M., & Gan, Y. (2019). Advances in particle shape engineering for improved drug delivery. Drug discovery today, 24(2), 575-583. https://doi.org/10.1016/j.drudis.2018.10.006
Yang, Yiwei, et al. "Advances in particle shape engineering for improved drug delivery." Drug discovery today vol. 24,2 (2019): 575-583. doi: https://doi.org/10.1016/j.drudis.2018.10.006
Yang Y, Nie D, Liu Y, Yu M, Gan Y. Advances in particle shape engineering for improved drug delivery. Drug Discov Today. 2019 Feb;24(2):575-583. doi: 10.1016/j.drudis.2018.10.006. Epub 2018 Oct 17. PMID: 30342244.
Copy Download .nbib Format: NLM
Industry update covering January 2021.

Therapeutic delivery

Simpson I.
PMID: 33876655
Ther Deliv. 2021 May;12(5):345-352. doi: 10.4155/tde-2021-0024. Epub 2021 Apr 20.

No abstract available.

Cite
Simpson I. Industry update covering January 2021. Ther Deliv. 2021;12(5):345-352doi: 10.4155/tde-2021-0024.
Simpson, I. (2021). Industry update covering January 2021. Therapeutic delivery, 12(5), 345-352. https://doi.org/10.4155/tde-2021-0024
Simpson, Iain. "Industry update covering January 2021." Therapeutic delivery vol. 12,5 (2021): 345-352. doi: https://doi.org/10.4155/tde-2021-0024
Simpson I. Industry update covering January 2021. Ther Deliv. 2021 May;12(5):345-352. doi: 10.4155/tde-2021-0024. Epub 2021 Apr 20. PMID: 33876655.
Copy Download .nbib Format: NLM
Protein-Templated Hit Identification through an Ugi Four-Component Reaction*.

Chemistry (Weinheim an der Bergstrasse, Germany)

Mancini F, Unver MY, Elgaher WAM, Jumde VR, Alhayek A, Lukat P, Herrmann J, Witte MD, Köck M, Blankenfeldt W, Müller R, Hirsch AKH.
PMID: 32428268
Chemistry. 2020 Nov 17;26(64):14585-14593. doi: 10.1002/chem.202002250. Epub 2020 Sep 30.

Kinetic target-guided synthesis represents an efficient hit-identification strategy, in which the protein assembles its own inhibitors from a pool of complementary building blocks via an irreversible reaction. Herein, we pioneered an in situ Ugi reaction for the identification of...

Cite
Mancini F, Unver MY, Elgaher WAM, et al. Protein-Templated Hit Identification through an Ugi Four-Component Reaction*. Chemistry. 2020;26(64):14585-14593doi: 10.1002/chem.202002250.
Mancini, F., Unver, M. Y., Elgaher, W. A. M., Jumde, V. R., Alhayek, A., Lukat, P., Herrmann, J., Witte, M. D., Köck, M., Blankenfeldt, W., Müller, R., & Hirsch, A. K. H. (2020). Protein-Templated Hit Identification through an Ugi Four-Component Reaction*. Chemistry (Weinheim an der Bergstrasse, Germany), 26(64), 14585-14593. https://doi.org/10.1002/chem.202002250
Mancini, Federica, et al. "Protein-Templated Hit Identification through an Ugi Four-Component Reaction*." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 26,64 (2020): 14585-14593. doi: https://doi.org/10.1002/chem.202002250
Mancini F, Unver MY, Elgaher WAM, Jumde VR, Alhayek A, Lukat P, Herrmann J, Witte MD, Köck M, Blankenfeldt W, Müller R, Hirsch AKH. Protein-Templated Hit Identification through an Ugi Four-Component Reaction*. Chemistry. 2020 Nov 17;26(64):14585-14593. doi: 10.1002/chem.202002250. Epub 2020 Sep 30. PMID: 32428268; PMCID: PMC7756422.
Copy Download .nbib Format: NLM
Transform nanomedicine with breakthrough thinking?.

Journal of controlled release : official journal of the Controlled Release Society

Cui H, Shen Y, Schiffelers RM, Hennink WE.
PMID: 33189787
J Control Release. 2021 Feb 10;330:1130-1131. doi: 10.1016/j.jconrel.2020.11.018. Epub 2020 Nov 13.

No abstract available.

Cite
Cui H, Shen Y, Schiffelers RM, et al. Transform nanomedicine with breakthrough thinking?. J Control Release. 2020;330:1130-1131doi: 10.1016/j.jconrel.2020.11.018.
Cui, H., Shen, Y., Schiffelers, R. M., & Hennink, W. E. (2021). Transform nanomedicine with breakthrough thinking?. Journal of controlled release : official journal of the Controlled Release Society, 3301130-1131. https://doi.org/10.1016/j.jconrel.2020.11.018
Cui, Honggang, et al. "Transform nanomedicine with breakthrough thinking?." Journal of controlled release : official journal of the Controlled Release Society vol. 330 (2021): 1130-1131. doi: https://doi.org/10.1016/j.jconrel.2020.11.018
Cui H, Shen Y, Schiffelers RM, Hennink WE. Transform nanomedicine with breakthrough thinking?. J Control Release. 2021 Feb 10;330:1130-1131. doi: 10.1016/j.jconrel.2020.11.018. Epub 2020 Nov 13. PMID: 33189787.
Copy Download .nbib Format: NLM
A quantitative view on multivalent nanomedicine targeting.

Advanced drug delivery reviews

Woythe L, Tito NB, Albertazzi L.
PMID: 33264593
Adv Drug Deliv Rev. 2021 Feb;169:1-21. doi: 10.1016/j.addr.2020.11.010. Epub 2020 Nov 29.

Although the concept of selective delivery has been postulated over 100 years ago, no targeted nanomedicine has been clinically approved so far. Nanoparticles modified with targeting ligands to promote the selective delivery of therapeutics towards a specific cell population...

Cite
Woythe L, Tito NB, Albertazzi L. A quantitative view on multivalent nanomedicine targeting. Adv Drug Deliv Rev. 2020;169:1-21doi: 10.1016/j.addr.2020.11.010.
Woythe, L., Tito, N. B., & Albertazzi, L. (2021). A quantitative view on multivalent nanomedicine targeting. Advanced drug delivery reviews, 1691-21. https://doi.org/10.1016/j.addr.2020.11.010
Woythe, Laura, et al. "A quantitative view on multivalent nanomedicine targeting." Advanced drug delivery reviews vol. 169 (2021): 1-21. doi: https://doi.org/10.1016/j.addr.2020.11.010
Woythe L, Tito NB, Albertazzi L. A quantitative view on multivalent nanomedicine targeting. Adv Drug Deliv Rev. 2021 Feb;169:1-21. doi: 10.1016/j.addr.2020.11.010. Epub 2020 Nov 29. PMID: 33264593.
Copy Download .nbib Format: NLM
Diagnostic and Therapeutic Nanomedicine.

Advances in experimental medicine and biology

Joo J.
PMID: 33834444
Adv Exp Med Biol. 2021;1310:401-447. doi: 10.1007/978-981-33-6064-8_15.

Nanotechnology has been widely applied to medical interventions for prevention, diagnostics, and therapeutics of diseases, and the application of nanotechnology for medical purposes, which is called as a term "nanomedicine" has received tremendous attention. In particular, the design and...

Cite
Joo J. Diagnostic and Therapeutic Nanomedicine. Adv Exp Med Biol. 2021;1310:401-447doi: 10.1007/978-981-33-6064-8_15.
Joo, J. (2021). Diagnostic and Therapeutic Nanomedicine. Advances in experimental medicine and biology, 1310401-447. https://doi.org/10.1007/978-981-33-6064-8_15
Joo, Jinmyoung. "Diagnostic and Therapeutic Nanomedicine." Advances in experimental medicine and biology vol. 1310 (2021): 401-447. doi: https://doi.org/10.1007/978-981-33-6064-8_15
Joo J. Diagnostic and Therapeutic Nanomedicine. Adv Exp Med Biol. 2021;1310:401-447. doi: 10.1007/978-981-33-6064-8_15. PMID: 33834444.
Copy Download .nbib Format: NLM
Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed.

Current topics in medicinal chemistry

Yadollahpour A.
PMID: 33292118
Curr Top Med Chem. 2020;20(30):2735-2736. doi: 10.2174/156802662030201110091740.

No abstract available.

Cite
Yadollahpour A. Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed. Curr Top Med Chem. 2020;20(30):2735-2736doi: 10.2174/156802662030201110091740.
Yadollahpour, A. (2020). Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed. Current topics in medicinal chemistry, 20(30), 2735-2736. https://doi.org/10.2174/156802662030201110091740
Yadollahpour, Ali. "Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed." Current topics in medicinal chemistry vol. 20,30 (2020): 2735-2736. doi: https://doi.org/10.2174/156802662030201110091740
Yadollahpour A. Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed. Curr Top Med Chem. 2020;20(30):2735-2736. doi: 10.2174/156802662030201110091740. PMID: 33292118.
Copy Download .nbib Format: NLM
Nanomedicines: promises and reality.

Drug discovery today

Lagarce F.
PMID: 31978388
Drug Discov Today. 2020 Mar;25(3):473-474. doi: 10.1016/j.drudis.2020.01.001. Epub 2020 Jan 21.

No abstract available.

Cite
Lagarce F. Nanomedicines: promises and reality. Drug Discov Today. 2020;25(3):473-474doi: 10.1016/j.drudis.2020.01.001.
Lagarce, F. (2020). Nanomedicines: promises and reality. Drug discovery today, 25(3), 473-474. https://doi.org/10.1016/j.drudis.2020.01.001
Lagarce, Frederic. "Nanomedicines: promises and reality." Drug discovery today vol. 25,3 (2020): 473-474. doi: https://doi.org/10.1016/j.drudis.2020.01.001
Lagarce F. Nanomedicines: promises and reality. Drug Discov Today. 2020 Mar;25(3):473-474. doi: 10.1016/j.drudis.2020.01.001. Epub 2020 Jan 21. PMID: 31978388.
Copy Download .nbib Format: NLM
Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System.

Current drug targets

Sherif AY, Harisa GI, Alanazi FK, Youssof AME.
PMID: 31309889
Curr Drug Targets. 2019;20(15):1537-1549. doi: 10.2174/1389450120666190715104100.

Targeting of therapeutic agents to their specific site of action not only increases the treatment efficacy, but also reduces systemic toxicity. Therefore, various drug delivery systems (DDSs) have been developed to achieve this target. However, most of those DDSs...

Cite
Sherif AY, Harisa GI, Alanazi FK, et al. Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System. Curr Drug Targets. 2019;20(15):1537-1549doi: 10.2174/1389450120666190715104100.
Sherif, A. Y., Harisa, G. I., Alanazi, F. K., & Youssof, A. M. E. (2019). Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System. Current drug targets, 20(15), 1537-1549. https://doi.org/10.2174/1389450120666190715104100
Sherif, Abdelrahman Y, et al. "Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System." Current drug targets vol. 20,15 (2019): 1537-1549. doi: https://doi.org/10.2174/1389450120666190715104100
Sherif AY, Harisa GI, Alanazi FK, Youssof AME. Engineering of Exosomes: Steps Towards Green Production of Drug Delivery System. Curr Drug Targets. 2019;20(15):1537-1549. doi: 10.2174/1389450120666190715104100. PMID: 31309889.
Copy Download .nbib Format: NLM
Three Decades of Research about the Corona Around Nanoparticles: Lessons Learned and Where to Go Now.

Small (Weinheim an der Bergstrasse, Germany)

Lundqvist M, Cedervall T.
PMID: 33107223
Small. 2020 Nov;16(46):e2000892. doi: 10.1002/smll.202000892. Epub 2020 Oct 26.

The research about how a nanoparticle (NP) interacts with a complex biological solution has been conducted, according to the literature, for almost three decades. A significant amount of data has been generated, especially in the last one and a...

Cite
Lundqvist M, Cedervall T. Three Decades of Research about the Corona Around Nanoparticles: Lessons Learned and Where to Go Now. Small. 2020;16(46):e2000892doi: 10.1002/smll.202000892.
Lundqvist, M., & Cedervall, T. (2020). Three Decades of Research about the Corona Around Nanoparticles: Lessons Learned and Where to Go Now. Small (Weinheim an der Bergstrasse, Germany), 16(46), e2000892. https://doi.org/10.1002/smll.202000892
Lundqvist, Martin, and Cedervall, Tommy. "Three Decades of Research about the Corona Around Nanoparticles: Lessons Learned and Where to Go Now." Small (Weinheim an der Bergstrasse, Germany) vol. 16,46 (2020): e2000892. doi: https://doi.org/10.1002/smll.202000892
Lundqvist M, Cedervall T. Three Decades of Research about the Corona Around Nanoparticles: Lessons Learned and Where to Go Now. Small. 2020 Nov;16(46):e2000892. doi: 10.1002/smll.202000892. Epub 2020 Oct 26. PMID: 33107223.
Copy Download .nbib Format: NLM
Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation.

Biomaterials science

Li S, Xu J, Qian J, Gao X.
PMID: 33155579
Biomater Sci. 2020 Dec 15;8(24):6978-6991. doi: 10.1039/d0bm01385d.

Extracellular vesicles (EVs) are receiving increasing attention in recent years in the field of cancer treatment. EVs contain specific contents closely related to their donor cells, such as miRNAs, proteins and dsDNAs. As endogenous vesicles, EVs naturally have the...

Cite
Li S, Xu J, Qian J, et al. Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation. Biomater Sci. 2020;8(24):6978-6991doi: 10.1039/d0bm01385d.
Li, S., Xu, J., Qian, J., & Gao, X. (2020). Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation. Biomaterials science, 8(24), 6978-6991. https://doi.org/10.1039/d0bm01385d
Li, Sha, et al. "Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation." Biomaterials science vol. 8,24 (2020): 6978-6991. doi: https://doi.org/10.1039/d0bm01385d
Li S, Xu J, Qian J, Gao X. Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation. Biomater Sci. 2020 Dec 15;8(24):6978-6991. doi: 10.1039/d0bm01385d. PMID: 33155579.
Copy Download .nbib Format: NLM
Advances of Nanoparticles for Leukemia Treatment.

ACS biomaterials science & engineering

Shen J, Lu Z, Wang J, Zhang T, Yang J, Li Y, Liu G, Zhang X.
PMID: 33320613
ACS Biomater Sci Eng. 2020 Dec 14;6(12):6478-6489. doi: 10.1021/acsbiomaterials.0c01040. Epub 2020 Nov 20.

Leukemia is a liquid tumor caused by a hematopoietic stem cell malignant clone, which seriously affects the normal function of the hematopoietic system. Conventional drugs have poor therapeutic effects due to their poor specificity and stability. With the development...

Cite
Shen J, Lu Z, Wang J, et al. Advances of Nanoparticles for Leukemia Treatment. ACS Biomater Sci Eng. 2020;6(12):6478-6489doi: 10.1021/acsbiomaterials.0c01040.
Shen, J., Lu, Z., Wang, J., Zhang, T., Yang, J., Li, Y., Liu, G., & Zhang, X. (2020). Advances of Nanoparticles for Leukemia Treatment. ACS biomaterials science & engineering, 6(12), 6478-6489. https://doi.org/10.1021/acsbiomaterials.0c01040
Shen, Jie, et al. "Advances of Nanoparticles for Leukemia Treatment." ACS biomaterials science & engineering vol. 6,12 (2020): 6478-6489. doi: https://doi.org/10.1021/acsbiomaterials.0c01040
Shen J, Lu Z, Wang J, Zhang T, Yang J, Li Y, Liu G, Zhang X. Advances of Nanoparticles for Leukemia Treatment. ACS Biomater Sci Eng. 2020 Dec 14;6(12):6478-6489. doi: 10.1021/acsbiomaterials.0c01040. Epub 2020 Nov 20. PMID: 33320613.
Copy Download .nbib Format: NLM
Showing 169 to 180 of 201 entries